DOBI Aims To Be $100 Mil. Firm Within A Year Of ComfortScan Launch
This article was originally published in The Gray Sheet
DOBI Medical Systems hopes to gain FDA approval in the third quarter of 2002 for its ComfortScan dynamic breast imaging system based on an ongoing, 10-center, 1,200 patient U.S. pivotal trial of the system for use as an adjunct to mammography
You may also be interested in...
Chugai's decision to spin off its wholly-owned diagnostic subsidiary Gen-Probe following a merger with Roche's Japanese unit, Nippon Roche, will preserve worldwide competition between Roche's Cobas AmpliScreen nucleic acid test (NAT) line and Chiron's Procleix NAT, developed with Gen-Probe
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.